# Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis

> **NCT04696666** · NA · UNKNOWN · sponsor: **LIDDE Therapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Hemorrhagic Cystitis

## Interventions

- **DEVICE:** INSTYLAN (Sodium Hyaluronate 80mg/50ml)

## Key facts

- **NCT ID:** NCT04696666
- **Lead sponsor:** LIDDE Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-15
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-07-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04696666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04696666, "Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04696666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*